A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)

Trial Profile

A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs TWB 103 (Primary)
  • Indications Wounds
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transwell Biotech
  • Most Recent Events

    • 13 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
    • 13 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2016 According an Elanix Biotechnologies media release, company has received IND clearance from the US FDA to conduct this trial. Patients enrolment at Taiwan and Japan location is expected by Q2 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top